NDAINJECTIONINJECTABLE
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
VISIPAQUE 270 (iodixanol) by GE HealthCare is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 1996.
Drug data last refreshed 19h ago
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Clinical Trials (4)
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
Started Oct 2011
255 enrolled
Drug Safety
Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
Started May 2011
304 enrolled
Patient Comfort and Safety
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
Started Mar 2009
23 enrolled
Chronic Renal ImpairmentDiabetes Mellitus
Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)
Started Jul 2005
50 enrolled
Coronary Artery Disease
Worked on VISIPAQUE 270 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.